Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy.
A patient is described in whom fatal myopathy occurred, and its cause appears to be the consequence of simvastatin therapy.
Boltan
David Demitry
DD
Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas 75205, USA.
Lachar
Whitney
W
Khetan
Anita
A
Bouffard
John-Paul
JP
Roberts
William Clifford
WC
D002114:Calcinosis / Q000473:pathology; D003680:Deglutition Disorders / Q000139:chemically induced; D004401:Dysarthria / Q000139:chemically induced; D004417:Dyspnea / Q000139:chemically induced; D017809:Fatal Outcome; D005355:Fibrosis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018485:Muscle Fibers, Skeletal / Q000473:pathology; D018908:Muscle Weakness / Q000139:chemically induced; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology; D009336:Necrosis; D019821:Simvastatin / Q000009:adverse effects*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019821:Simvastatin